Navigation Links
The Treatment Landscape for Hepatocellular Carcinoma Will Change Dramatically Over the Next Ten Years Due to the Launch of New Therapies in the United States and EU5
Date:1/29/2013

BURLINGTON, Mass., Jan. 29, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that the treatment landscape for hepatocellular carcinoma in the United States and Europe will change dramatically through 2021 as three new, potentially high priced therapies–Novartis's Afinitor, ArQule's tivantinib and Celsion's ThermoDox–arrive on the market, thereby greatly increasing treatment options in patient populations in which there is no approved standard-of-care drug therapy.

According to Niche Markets and Rare Diseases: Hepatocellular Carcinoma, of the forecasted emerging therapies, Afinitor will be the first drug to gain regulatory approval and will launch in 2014 in all markets under study for treatment of advanced hepatocellular carcinoma in the second-line setting following disease progression on Bayer HealthCare/Onyx Pharmaceuticals' Nexavar, the current patient-share leader. By 2021, tivantinib will also launch in the second-line setting for treatment of patients who express high levels of c-MET. ThermoDox, a heat-sensitive liposome-encapsulated formulation of doxorubicin, will be the only therapy to launch over the next ten years in the localized/locally advanced setting for use in combination with radiofrequency embolization (RFA).

"According to opinion leaders, one of the greatest unmet needs in the hepatocellular carcinoma space is for a second-line therapy directed at patients who cannot tolerate treatment with or progress on Nexavar–the standard-of-care in the first-line setting through 2021," said Decision Resources Analyst Karen Pomeranz , Ph.D. "However, the launch of ThermoDox will herald a novel treatment approach in loc
'/>"/>

SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
2. Aethlon Medical Note: An Unprecedented Data Point, The Single-Treatment Capture of Hepatitis C Virus (HCV) by the Aethlon Hemopurifier®
3. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
4. Accuray Launches First Study to Compare CyberKnife® SBRT to Surgery and IMRT for Treatment of Early-Stage Prostate Cancer
5. Elekta, pioneer in treatment of cancer in brain disorders, to Move North America Headquarters to Atlanta
6. Ampio Awarded US and Canadian Patents that will Bolster the Commercialization of Optina™ for the treatment of Diabetic Macular Edema (DME)
7. National Patient Advocate Foundation Praises Signing of the Delaware Cancer Treatment Access Act into Law
8. Zogenix Submits New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Zohydro™ for Treatment of Chronic Pain
9. Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism
10. Study Results Demonstrate Analytical Treatment Interruption to Assess Antiviral Activity of Argoss Arcelis™ Personalized Immunotherapy for Treatment of HIV Patients, AGS-004, Is Acceptable Strategy for At Least 16 Weeks
11. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... Va. , July 28, 2014  Serco ... services, announced the Company has been awarded a ... Support Command (NEMSCOM) and its Deployable Medical Systems.  ... enable medical personnel to provide world-class healthcare to ... operating environment across the globe. The five year ...
(Date:7/28/2014)... Ala. , July 28, 2014 ... J. Tipton , Ph.D., President and CEO of ... the Controlled Release Society (CRS) for the 2014-2015 ... annual meeting on July 12 in ... 40 countries.  The Controlled Release ...
(Date:7/28/2014)... Texas , July 28, 2014  MedSpring Urgent Care, an ... walk-in clinic at 517 S. Lamar Blvd., Austin, TX ... care clinic is located on the southeast corner of Barton ... on-site from 9 a.m. - 9 p.m. daily, including weekends and ... of Texas, Central Austin , Anderson Mill ...
Breaking Medicine Technology:Serco Awarded $22.7 Million Contract to Support Deployable Medical Systems 2Arthur J. Tipton, Ph.D., Named President of Controlled Release Society 2Arthur J. Tipton, Ph.D., Named President of Controlled Release Society 3MedSpring Urgent Care opens Barton Springs walk-in clinic in Austin, TX 2
... May Offer Long-Lasting ... OLDSMAR, Fla., Aug. 25 Time. It is a precious,commodity. ... enough,of it. And the small amount of time a woman spends ... time she invests in others.,This reality has led many women in ...
... Front Line CLL, NHL and CLL Retreatment and Japanese Development Studies ... ... Genmab has,announced plans to begin four studies of ofatumumab in chronic ... to begin four studies of,ofatumumab in chronic lymphocytic leukemia (CLL) and follicular,non-Hodgkin,s ...
Cached Medicine Technology:Going Beyond 'Spa Day': Giving Women the Opportunity to Do Something Proactive Which May Lead to Long Term Health Benefits 2Genmab Announces Upcoming Ofatumumab Studies 2Genmab Announces Upcoming Ofatumumab Studies 3Genmab Announces Upcoming Ofatumumab Studies 4
(Date:7/28/2014)... 2014 The report, “Blowing Agents ... - Trends and Forecasts to 2019” defines and ... and forecasting of the global consumption volume and ... tables with 39 figures spread through 226 Pages ... http://www.marketsandmarkets.com/Market-Reports/blowing-agents-market-71329121.html , Blowing agents are highly utilized ...
(Date:7/28/2014)... NJ (PRWEB) July 28, 2014 ... representing the majority of professionals engaged in the ... of the Transplantation and Immunology Research Network ... transplantation and immunology research. As modern organ transplantation ... a network that could provide more opportunities for ...
(Date:7/28/2014)... treatment for patients with one of the UK,s most ... , Chronic obstructive pulmonary disease (COPD) is the name ... due to long-term damage to the lungs. Often ... cent of all hospital admissions in the UK, with ... after they are discharged. , A team ...
(Date:7/28/2014)... 2014 With California in a record ... news that a fire blanket that is ... under development by SunSeeker Enterprises, Inc. The fire blanket—utilizing ... from the extreme heat of re-entry into the Earth's ... homes. , “Our firefighters routinely lay their very lives ...
(Date:7/28/2014)... Windsor, Co (PRWEB) July 28, 2014 ... Colorado has unveiled new plans to raise investment capital ... growing 24/7 fitness concept in the United States. , ... increasing popularity of 24/7 fitness centers provide a great ... into this rapidly expanding space. In addition to this, ...
Breaking Medicine News(10 mins):Health News:Blowing Agents Market is Poised to Reach 452.0 Kilotons at CAGR of 5.8% by 2019 – Report by MarketsandMarkets 2Health News:Blowing Agents Market is Poised to Reach 452.0 Kilotons at CAGR of 5.8% by 2019 – Report by MarketsandMarkets 3Health News:Blowing Agents Market is Poised to Reach 452.0 Kilotons at CAGR of 5.8% by 2019 – Report by MarketsandMarkets 4Health News:American Society of Transplantation (AST) Launches Transplantation and Immunology Research Network (TIRN); Aims to Expand Research Collaboration & Funding 2Health News:American Society of Transplantation (AST) Launches Transplantation and Immunology Research Network (TIRN); Aims to Expand Research Collaboration & Funding 3Health News:New research to tackle treatment for lung disease 2Health News:New research to tackle treatment for lung disease 3Health News:Revolutionary Fire Blanket Offers Over 200 Percent More Fire Protection to Firefighters and Homes 2Health News:Pro Bodybuilder Drorit Silverman Confirms Plans to Raise Money for Investment in the Popular 24/7 Fitness Concept 2
... A new exhibition hall dedicated to the discovery ... at the Smithsonian,s National Museum of Natural History. Based on ... Koch (pronounced "coke") Hall of Human Origins will open to ... 3 p.m. Wednesday, March 17, which also marks the ...
... (March 16, 2010)One of the most dangerous characteristics of cancer ... For this reason, oncologists have a major need for better ... to travel to other parts of the body. Effective ... (CTC,s), could help guide treatment and improve quality of life ...
... 16, 2010 The AIUM is pleased to ... AIUM to endorse the recent AIUM Training Guidelines ... guidelines allow for a several practitioners, including physicians, ... ultrasound examinations, marking significant promise for the future ...
... , ... online survey by Jackson Healthcare, 89 percent of physicians agree that patients receiving negligent treatment ... Alpharetta, ... Healthcare , 89 percent of physicians agree that patients receiving negligent treatment deserve fair compensation. ...
... arterial disease can avoid amputation, researchers find , TUESDAY, ... with severe peripheral arterial disease may now have another ... artery below the knee might re-establish blood flow, new ... severe form of peripheral arterial disease (PAD), causes more ...
... died soon after than those using Brilinta, study ... a trial comparing two anti-clotting drugs, patients given Brilinta ... than those given Plavix, researchers found. , Both drugs ... the more popular drug, has been linked to potentially ...
Cached Medicine News:Health News:New Exhibition Hall Devoted to Human Origins Opens at National Museum of Natural History 2Health News:New Exhibition Hall Devoted to Human Origins Opens at National Museum of Natural History 3Health News:New Exhibition Hall Devoted to Human Origins Opens at National Museum of Natural History 4Health News:New Exhibition Hall Devoted to Human Origins Opens at National Museum of Natural History 5Health News:New Exhibition Hall Devoted to Human Origins Opens at National Museum of Natural History 6Health News:Revisiting the need to detect circulating tumor cells 2Health News:Unprecedented AIUM training guidelines speak to future of musculoskeletal ultrasound 2Health News:Recent Survey Reveals That Physicians Overwhelmingly Support Patient Compensation When Harmed 2Health News:Recent Survey Reveals That Physicians Overwhelmingly Support Patient Compensation When Harmed 3Health News:Stenting May Save Legs 2Health News:Stenting May Save Legs 3Health News:Newer Blood Thinner Beats Plavix for Bypass Patients 2Health News:Newer Blood Thinner Beats Plavix for Bypass Patients 3
Inquire...
... (Low Melt), A low temperature agarose ... temperature , Optimal for in-gel restriction digestion/ligation ... a very manageable clear gel that provides ... at approximately 65°C and remains fluid at ...
... UltraClean Agarose, Molecular Biology ... electrophoretic separation of nucleic acids. ... isolate DNA fragments from 0.2 ... of UltraClean Agarose is tested ...
... Agarose 1000 is specifically formulated for high ... fragments <1000 bp. This standard melting temperature ... little as 10 bp difference in size. ... strong gel structure for better handling and ...
Medicine Products: